169 related articles for article (PubMed ID: 28718307)
1. Late post-treatment radiographic changes 3 years following chemoradiation for glioma: the importance of histopathology.
Galante JR; Rodriguez F; Grossman SA; Strowd RE
CNS Oncol; 2017 Jul; 6(3):195-201. PubMed ID: 28718307
[TBL] [Abstract][Full Text] [Related]
2. Pseudoprogression: relevance with respect to treatment of high-grade gliomas.
Fink J; Born D; Chamberlain MC
Curr Treat Options Oncol; 2011 Sep; 12(3):240-52. PubMed ID: 21594589
[TBL] [Abstract][Full Text] [Related]
3. Defining Treatment-Related Adverse Effects in Patients with Glioma: Distinctive Features of Pseudoprogression and Treatment-Induced Necrosis.
Winter SF; Vaios EJ; Muzikansky A; Martinez-Lage M; Bussière MR; Shih HA; Loeffler J; Karschnia P; Loebel F; Vajkoczy P; Dietrich J
Oncologist; 2020 Aug; 25(8):e1221-e1232. PubMed ID: 32488924
[TBL] [Abstract][Full Text] [Related]
4. Contrast enhancing spots as a new pattern of late onset pseudoprogression in glioma patients.
Voss M; Franz K; Steinbach JP; Fokas E; Forster MT; Filipski K; Hattingen E; Wagner M; Breuer S
J Neurooncol; 2019 Mar; 142(1):161-169. PubMed ID: 30604393
[TBL] [Abstract][Full Text] [Related]
5. Distinct imaging patterns of pseudoprogression in glioma patients following proton versus photon radiation therapy.
Ritterbusch R; Halasz LM; Graber JJ
J Neurooncol; 2021 May; 152(3):583-590. PubMed ID: 33751335
[TBL] [Abstract][Full Text] [Related]
6. Pseudoprogression and pseudoresponse in the management of high-grade glioma : optimal decision timing according to the response assessment of the neuro-oncology working group.
Chang JH; Kim CY; Choi BS; Kim YJ; Kim JS; Kim IA
J Korean Neurosurg Soc; 2014 Jan; 55(1):5-11. PubMed ID: 24570811
[TBL] [Abstract][Full Text] [Related]
7. Parametric response map as an imaging biomarker to distinguish progression from pseudoprogression in high-grade glioma.
Tsien C; Galbán CJ; Chenevert TL; Johnson TD; Hamstra DA; Sundgren PC; Junck L; Meyer CR; Rehemtulla A; Lawrence T; Ross BD
J Clin Oncol; 2010 May; 28(13):2293-9. PubMed ID: 20368564
[TBL] [Abstract][Full Text] [Related]
8. Pseudoprogression after radiotherapy with concurrent temozolomide for high-grade glioma: clinical observations and working recommendations.
Chaskis C; Neyns B; Michotte A; De Ridder M; Everaert H
Surg Neurol; 2009 Oct; 72(4):423-8. PubMed ID: 19150114
[TBL] [Abstract][Full Text] [Related]
9. Post-ictal changes presenting as late pseudoprogression on MRI and PET in a patient with diffuse glioma: Case report and brief literature review.
Nair SM; Sahu A; Dasgupta A; Puranik A; Gupta T
Neuroradiol J; 2024 Apr; 37(2):229-233. PubMed ID: 37002537
[TBL] [Abstract][Full Text] [Related]
10. Incidence of Tumour Progression and Pseudoprogression in High-Grade Gliomas: a Systematic Review and Meta-Analysis.
Abbasi AW; Westerlaan HE; Holtman GA; Aden KM; van Laar PJ; van der Hoorn A
Clin Neuroradiol; 2018 Sep; 28(3):401-411. PubMed ID: 28466127
[TBL] [Abstract][Full Text] [Related]
11. Pseudoprogression in high-grade glioma.
Knudsen-Baas KM; Moen G; Fluge Ø; Storstein A
Acta Neurol Scand Suppl; 2013; (196):31-7. PubMed ID: 23190289
[TBL] [Abstract][Full Text] [Related]
12. FET PET Radiomics for Differentiating Pseudoprogression from Early Tumor Progression in Glioma Patients Post-Chemoradiation.
Lohmann P; Elahmadawy MA; Gutsche R; Werner JM; Bauer EK; Ceccon G; Kocher M; Lerche CW; Rapp M; Fink GR; Shah NJ; Langen KJ; Galldiks N
Cancers (Basel); 2020 Dec; 12(12):. PubMed ID: 33353180
[TBL] [Abstract][Full Text] [Related]
13. The diagnostic accuracy of detecting malignant transformation of low-grade glioma using O-(2-[18F]fluoroethyl)-l-tyrosine positron emission tomography: a retrospective study.
Bashir A; Brennum J; Broholm H; Law I
J Neurosurg; 2018 Apr; 130(2):451-464. PubMed ID: 29624154
[TBL] [Abstract][Full Text] [Related]
14. Longitudinal DSC-MRI for Distinguishing Tumor Recurrence From Pseudoprogression in Patients With a High-grade Glioma.
Boxerman JL; Ellingson BM; Jeyapalan S; Elinzano H; Harris RJ; Rogg JM; Pope WB; Safran H
Am J Clin Oncol; 2017 Jun; 40(3):228-234. PubMed ID: 25436828
[TBL] [Abstract][Full Text] [Related]
15. Histopathologically confirmed radiation-induced damage of the brain - an in-depth analysis of radiation parameters and spatio-temporal occurrence.
Kossmann MRP; Ehret F; Roohani S; Winter SF; Ghadjar P; Acker G; Senger C; Schmid S; Zips D; Kaul D
Radiat Oncol; 2023 Dec; 18(1):198. PubMed ID: 38087368
[TBL] [Abstract][Full Text] [Related]
16. The Utility of Conventional Amino Acid PET Radiotracers in the Evaluation of Glioma Recurrence also in Comparison with MRI.
Santo G; Laudicella R; Linguanti F; Nappi AG; Abenavoli E; Vergura V; Rubini G; Sciagrà R; Arnone G; Schillaci O; Minutoli F; Baldari S; Quartuccio N; Bisdas S
Diagnostics (Basel); 2022 Mar; 12(4):. PubMed ID: 35453892
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic accuracy of glioma pseudoprogression identification with positron emission tomography imaging: a systematic review and meta-analysis.
Ouyang ZQ; Zheng GR; Duan XR; Zhang XR; Ke TF; Bao SS; Yang J; He B; Liao CD
Quant Imaging Med Surg; 2023 Aug; 13(8):4943-4959. PubMed ID: 37581048
[TBL] [Abstract][Full Text] [Related]
18. Rescue bevacizumab following symptomatic pseudoprogression of a tectal glioma post-radiotherapy: a case report and review of the literature.
Nguyen TK; Perry J; Sundaram ANE; Detsky J; Maralani PJ; Calabrese E; Das S; Sahgal A
J Neurooncol; 2019 Jul; 143(3):475-481. PubMed ID: 31054097
[TBL] [Abstract][Full Text] [Related]
19.
Parent EE; Johnson DR; Gleason T; Villanueva-Meyer JE
Neurooncol Pract; 2021 Oct; 8(5):518-525. PubMed ID: 34594566
[TBL] [Abstract][Full Text] [Related]
20. Treatment-related brain tumor imaging changes: So-called "pseudoprogression" vs. tumor progression: Review and future research opportunities.
Tran DK; Jensen RL
Surg Neurol Int; 2013; 4(Suppl 3):S129-35. PubMed ID: 23682339
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
